News and events

March 12, 2018

InSysBio today announced their participation at AAT-AD/PD Focus Meeting 2018, to be held in Torino, Italy, on March 15-18, 2018. The Meeting is focused on all the latest breakthroughs in treatment and research in Alzheimer’s, Parkinson’s and other neurological diseases. Alexander Stepanov will present “In silico implementation of tauopathy transgenic mouse model” in the framework of session “Symposium 25: Tau in translational studies (2)”.

InSysBio modelers evaluated tau protein phosphorylation related targets for Alzheimer’s disease treatment

February 26, 2018

InSysBio continues to investigate the mechanisms underlying Alzheimer’s disease (AD) using the quantitative systems pharmacology (QSP) modeling approach. The part of QSP model describing tau protein was published in the PLOS ONE journal. This is one of more than dozen InSysBio publications in AD area during last seven years.

InSysBio Annual Internal Scientific Meeting

February 20, 2018

14-16 February 2018 InSysBio held Annual Internal Scientific Meeting.

New style

Moscow, Russia October 10, 2017 – InSysBio LLC, one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for the drug development, announced a renewal of the corporate identity.

Computer model showed an optimal anti-amyloid treatment

Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.

InSysBio will present at the American Conference on Pharmacometrics (ACoP8)!

Moscow, Russia, July 26, 2017. - Event announcement. This year the scientific team of InSysBio will make 9 poster presentations in conjunction with leading pharmaceutical companies at ACoP8. Also at the special session "QSP Modular design - Approaches to speed up the QSP model development" Oleg Demin Jr will hold a workshop on modeling with the Immune Response Template (IRT) platform.

InSysBio LLC Announce Renewal of Agreement with ASTEX Pharmaceuticals Inc.

Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.

To predict unpredictable: a platform for modeling of the high-selective oncology drugs was created

Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.

System pharmacology modelers throw light on drug discovery in Alzheimer's

Moscow, Russia - 21 June, 2017. InSysBio scientific group led by Tatiana Karelina developed a quantitative system pharmacology model of Alzheimer’s disease. First part published in CPT PSP shows how to design initial phases of clinical trials of new drugs and to interpret the data obtained.

InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017

Moscow, Russia - May 23, 2017. InSysBio CEO Oleg Demin gives a talk at the 6th FIP Pharmaceutical Sciences World Congress2017. He will speak about how to use QSP modeling to investigate drug safety at different stages of development.